Company
Dracen Pharmaceuticals
Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.
Also known as DRACEN PHARMACEUTICALS, INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- DRACEN PHARMACEUTICALS, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types. Our goal in treating cancers is to directly shrink tumors and remodel the tumor microenvironment to make it more conducive to immuno-oncology approaches, to gain greater disease control, increase anti-tumor responses and extend patient survival in areas of unmet need.
Funding snapshot
- Total raised
- $19.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $2.3M2023-06-11
Funding rounds
- Round, 2023
- $2.3M2023-06-11, SEC form D sold, 6 investors
- Round, 2021
- $8.6M2021-11-01, SEC form D sold, 8 investors
- Round, 2018
- $8.5M2018-01-11, SEC form D sold, 9 investors
Products
- Other
- DRP-104 (sirpiglenastat)
Loading relationship preview